Clinic, pathogenic mechanisms and drug testing of two inherited thrombocytopenias, ANKRD26-related Thrombocytopenia and MYH9-related diseases
- 1 November 2018
- journal article
- review article
- Published by Elsevier BV in European Journal of Medical Genetics
- Vol. 61 (11), 715-722
- https://doi.org/10.1016/j.ejmg.2018.01.014
Abstract
No abstract availableKeywords
Funding Information
- ERA-Net for Research Programs on Rare Diseases (EUPLANE)
This publication has 88 references indexed in Scilit:
- RUNX1-induced silencing of non-muscle myosin heavy chain IIB contributes to megakaryocyte polyploidizationNature Communications, 2012
- Ankrd26 Gene Disruption Enhances Adipogenesis of Mouse Embryonic FibroblastsJournal of Biological Chemistry, 2011
- Genome-wide Analysis of Simultaneous GATA1/2, RUNX1, FLI1, and SCL Binding in Megakaryocytes Identifies Hematopoietic RegulatorsDevelopmental Cell, 2011
- Mutations in the 5′ UTR of ANKRD26, the Ankirin Repeat Domain 26 Gene, Cause an Autosomal-Dominant Form of Inherited Thrombocytopenia, THC2American Journal of Human Genetics, 2011
- New Opportunities for an Ancient MaterialScience, 2010
- Non-muscle myosin II takes centre stage in cell adhesion and migrationNature Reviews Molecular Cell Biology, 2009
- Multiple Regulatory Steps Control Mammalian Nonmuscle Myosin II Assembly in Live CellsMolecular Biology of the Cell, 2009
- Localization in stereocilia, plasma membrane, and mitochondria suggests diverse roles for NMHC-IIa within cochlear hair cellsBrain Research, 2008
- A model for obesity and gigantism due to disruption of the Ankrd26 geneProceedings of the National Academy of Sciences, 2008
- New thrombopoietic growth factorsBlood, 2007